Plant Name: Polygonum cuspidatum
Taxonomic Information:
Plant ID: NPO11391
Plant Latin Name: Polygonum cuspidatum
Taxonomy Genus: Polygonum
Taxonomy Family: Polygonaceae
Plant External Links:
NCBI TaxonomyDB:
83819
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMGeographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; TSHR; | |
| ALPL; TDP1; PIK3CA; PIK3CB; HSD17B1; HSD17B2; HSD17B10; NQO2; ALOX12; GFER; NOX4; POLB; | |
| ACHE; BCHE; | |
| BCL2; | |
| STK3; CLK2; MET; PRKCQ; MAP4K4; MARK4; TBK1; FLT1; TYRO3; JAK2; CDK8; MAP3K10; CSNK2A1; JAK3; PDGFRA; FLT3; ROCK2; TAOK1; IGF1R; PTK2; AURKB; DYRK1A; GSK3B; CAMK2A; CAMK1D; CAMKK2; GRK5; SGK2; CDK1; CSNK1A1; SIK2; PIM1; ALK; LRRK2; MAPK10; HCK; MARK3; ACVR1; ROS1; RET; IKBKE; DYRK1B; FGFR1; AXL; KDR; BTK; LTK; PRKX; TNK2; MELK; | |
| CA7; CA14; CA12; CA9; CA4; CA2; | |
| ESR1; ESR2; | |
| KDM4E; | |
| PTGS2; TYR; | |
| MMP2; MMP9; MMP1; | |
| AHR; NFKB1; | |
| FUT7; | |
| LMNA; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CSNK1A1 | Casein kinase I alpha | P48729 | CHEMBL2793 |
| Protein Kinase | SIK2 | Serine/threonine-protein kinase SIK2 | Q9H0K1 | CHEMBL5699 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | LRRK2 | Leucine-rich repeat serine/threonine-protein kinase 2 | Q5S007 | CHEMBL1075104 |
| Protein Kinase | MAPK10 | c-Jun N-terminal kinase 3 | P53779 | CHEMBL2637 |
| Protein Kinase | HCK | Tyrosine-protein kinase HCK | P08631 | CHEMBL3234 |
| Protein Kinase | MARK3 | Serine/threonine-protein kinase c-TAK1 | P27448 | CHEMBL5600 |
| Protein Kinase | ACVR1 | Activin receptor type-1 | Q04771 | CHEMBL5903 |
| Protein Kinase | ROS1 | Proto-oncogene tyrosine-protein kinase ROS | P08922 | CHEMBL5568 |
| Protein Kinase | RET | Tyrosine-protein kinase receptor RET | P07949 | CHEMBL2041 |
| Protein Kinase | IKBKE | Inhibitor of nuclear factor kappa B kinase epsilon subunit | Q14164 | CHEMBL3529 |
| Protein Kinase | DYRK1B | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Q9Y463 | CHEMBL5543 |
| Protein Kinase | FGFR1 | Fibroblast growth factor receptor 1 | P11362 | CHEMBL3650 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | BTK | Tyrosine-protein kinase BTK | Q06187 | CHEMBL5251 |
| Protein Kinase | LTK | Leukocyte tyrosine kinase receptor | P29376 | CHEMBL5627 |
| Protein Kinase | PRKX | Serine/threonine-protein kinase PRKX | P51817 | CHEMBL5818 |
| Protein Kinase | TNK2 | Tyrosine kinase non-receptor protein 2 | Q07912 | CHEMBL4599 |
| Protein Kinase | MELK | Maternal embryonic leucine zipper kinase | Q14680 | CHEMBL4578 |
| Protein Kinase | STK3 | Serine/threonine-protein kinase MST2 | Q13188 | CHEMBL4708 |
| Protein Kinase | CLK2 | Dual specificity protein kinase CLK2 | P49760 | CHEMBL4225 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | PRKCQ | Protein kinase C theta | Q04759 | CHEMBL3920 |
| Protein Kinase | MAP4K4 | Mitogen-activated protein kinase kinase kinase kinase 4 | O95819 | CHEMBL6166 |
| Protein Kinase | MARK4 | MAP/microtubule affinity-regulating kinase 4 | Q96L34 | CHEMBL5754 |
| Protein Kinase | TBK1 | Serine/threonine-protein kinase TBK1 | Q9UHD2 | CHEMBL5408 |
| Protein Kinase | FLT1 | Vascular endothelial growth factor receptor 1 | P17948 | CHEMBL1868 |
| Protein Kinase | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Q06418 | CHEMBL5314 |
| Protein Kinase | JAK2 | Tyrosine-protein kinase JAK2 | O60674 | CHEMBL2971 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | MAP3K10 | Mitogen-activated protein kinase kinase kinase 10 | Q02779 | CHEMBL2873 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | JAK3 | Tyrosine-protein kinase JAK3 | P52333 | CHEMBL2148 |
| Protein Kinase | PDGFRA | Platelet-derived growth factor receptor alpha | P16234 | CHEMBL2007 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | ROCK2 | Rho-associated protein kinase 2 | O75116 | CHEMBL2973 |
| Protein Kinase | TAOK1 | Serine/threonine-protein kinase TAO1 | Q7L7X3 | CHEMBL5261 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CAMK2A | CaM kinase II alpha | Q9UQM7 | CHEMBL4147 |
| Protein Kinase | CAMK1D | CaM kinase I delta | Q8IU85 | CHEMBL5073 |
| Protein Kinase | CAMKK2 | CaM-kinase kinase beta | Q96RR4 | CHEMBL5284 |
| Protein Kinase | GRK5 | G protein-coupled receptor kinase 5 | P34947 | CHEMBL5678 |
| Protein Kinase | SGK2 | Serine/threonine-protein kinase Sgk2 | Q9HBY8 | CHEMBL5794 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 8.968E-13 | 2.122E-10 | BTK, HCK, IGF1R, JAK2, JAK3, KDR, PTK2, ROS1, TNK2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.473E-11 | 8.470E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 9.564E-11 | 1.721E-08 | BTK, DYRK1A, HCK, JAK2, JAK3, MELK, PTK2, TNK2 |
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 9.610E-10 | 1.516E-07 | AURKB, CLK2, DYRK1A, DYRK1B, LRRK2, MAPK10, TNK2 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.518E-09 | 3.704E-07 | AXL, FGFR1, MET, NOX4, PDGFRA, PIK3CA, PIK3CB, PTK2, STK3, THPO |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.596E-08 | 2.132E-06 | FLT1, FLT3, KDR, PDGFRA |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 2.532E-08 | 3.281E-06 | FGFR1, FLT1, FLT3, JAK2, KDR, PDGFRA, PTK2 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 4.680E-08 | 5.791E-06 | AXL, FLT1, KDR, PIK3CA, PIK3CB, PTK2, ROCK2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.655E-08 | 6.841E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.500E-08 | 7.734E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.535E-08 | 7.734E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 9.553E-08 | 1.118E-05 | AHR, AXL, BCL2, CSNK2A1, DYRK1A, ESR1, GSK3B, MAPK10, PDGFRA, ROCK2, TYRO3 |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.483E-07 | 1.661E-05 | IGF1R, JAK2, PIK3CA, PIK3CB |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.599E-07 | 1.768E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, JAK2, NOX4, PTGS2 |
| BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 6.047E-07 | 6.096E-05 | FLT1, FLT3, KDR, PDGFRA |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.976E-07 | 7.001E-05 | CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 7.724E-07 | 7.610E-05 | AXL, BTK, CAMKK2, CDK1, CYP1B1, MMP9, PDGFRA |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.635E-34 | 3.560E-31 | ACVR1, ALK, AURKB, AXL, BTK, CAMK1D, CAMK2A, CAMKK2, CDK1, CDK8, CLK2, CSNK1A1, CSNK2A1, DYRK1A, DYRK1B, FGFR1, FLT1, FLT3, GRK5, GSK3B, HCK, IGF1R, IKBKE, JAK2, JAK3, KDR, LRRK2, LTK, MAP3K10, MAP4K4, MAPK10, MARK3, MARK4, MELK, MET, PDGFRA, PIK3CA, PIK3CB, PIM1, PRKCQ, PRKX, PTK2, RET, ROCK2, ROS1, SGK2, SIK2, STK3, TAOK1, TBK1, TNK2, TYRO3 |
| BP | GO:0009987; cellular process | GO:0008631; intrinsic apoptotic signaling pathway in response to oxidative stress | 1.047E-06 | 1.022E-04 | BCL2, CYP1B1, JAK2, MELK |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 1.126E-06 | 1.085E-04 | BTK, HCK, JAK2, JAK3, PTK2, TNK2 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 3.492E-06 | 3.169E-04 | BCHE, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 4.099E-06 | 3.685E-04 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, GFER, GSK3B, HSD17B1, HSD17B10, HSD17B2, KDM4E, NOX4, NQO2, PTGS2, TYR |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 5.068E-06 | 4.504E-04 | ALK, CDK1, LRRK2, MAP3K10, MAPK10, PIK3CB, TAOK1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 6.019E-06 | 5.264E-04 | ALPL, CYP1A1, CYP1B1, ESR1, FLT3, LRRK2, NFKB1, NOX4, PTGS2, ROCK2 |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 9.169E-06 | 7.799E-04 | BCL2, GSK3B, KDR, PIK3CB, PTK2, ROCK2 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.000E-05 | 8.410E-04 | AXL, IGF1R, JAK2, TYRO3 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 1.084E-05 | 9.082E-04 | ACHE, ALOX12, CSNK2A1, CYP19A1, CYP1A1, CYP3A4, FGFR1, HSD17B1, HSD17B2, PIK3CA, PIK3CB, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.150E-05 | 9.559E-04 | FLT1, FLT3, PDGFRA, PTK2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.185E-05 | 9.738E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 1.480E-05 | 1.193E-03 | FGFR1, MET, PDGFRA, PIK3CA, PIK3CB |
| BP | GO:0065007; biological regulation | GO:0010863; positive regulation of phospholipase C activity | 1.699E-05 | 1.345E-03 | ESR1, FGFR1, FLT1, PDGFRA |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.829E-05 | 1.432E-03 | ACVR1, AXL, BCL2, BTK, CA2, CAMK1D, FGFR1, JAK2, KDR, LTK, NFKB1, PTGS2, RET, STK3, THPO |
| BP | GO:0051179; localization | GO:0033160; positive regulation of protein import into nucleus, translocation | 2.158E-05 | 1.637E-03 | CDK1, JAK2, LRRK2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.195E-05 | 1.643E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 2.195E-05 | 1.643E-03 | ACHE, BCHE |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 2.304E-05 | 1.718E-03 | CAMK2A, FGFR1, JAK2, JAK3, MET, PDGFRA, PTK2, RET |
| CC | GO:0043226; organelle | GO:0005634; nucleus | 2.462E-05 | 1.824E-03 | ACHE, AHR, AURKB, BCL2, BTK, CAMK1D, CAMK2A, CAMKK2, CDK1, CDK8, CLK2, CSNK2A1, DYRK1A, DYRK1B, ESR1, ESR2, FLT3, GSK3B, IKBKE, JAK2, KDM4E, KDR, LMNA, LRRK2, MAPK10, MELK, MMP2, NFKB1, NOX4, PDGFRA, PIK3CB, PIM1, POLB, PRKX, PTGS2, PTK2, ROCK2, SIK2, STK3, TDP1, TNK2, TYR, TYRO3 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.796E-05 | 2.016E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:2001028; positive regulation of endothelial cell chemotaxis | 2.796E-05 | 2.016E-03 | FGFR1, KDR, MET |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 3.455E-05 | 2.411E-03 | ACVR1, FGFR1, FLT1, IGF1R, KDR, PDGFRA |
| BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 4.256E-05 | 2.934E-03 | ACHE, AXL, BCL2, CA2, CAMK1D, CAMK2A, CDK1, CYP19A1, FGFR1, GSK3B, JAK2, LRRK2, NPSR1, PTGS2, SGK2 |
| BP | GO:0008152; metabolic process | GO:0010468; regulation of gene expression | 4.435E-05 | 3.046E-03 | ACVR1, AHR, ALK, AURKB, BCL2, BTK, CA9, CAMK1D, CAMK2A, CAMKK2, CDK1, CDK8, CLK2, CSNK2A1, CYP1A2, CYP1B1, DYRK1A, DYRK1B, ESR1, ESR2, FGFR1, GSK3B, HCK, JAK2, KDM4E, KDR, LRRK2, MAP3K10, MAPK10, MET, NFKB1, PIK3CA, PIK3CB, PIM1, PRKCQ, RET, ROCK2, ROS1, STK3, TBK1 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 4.467E-05 | 3.049E-03 | AHR, ALOX12, AURKB, BCL2, BTK, CA2, CA7, CAMK2A, CAMKK2, CDK1, CSNK1A1, CSNK2A1, FGFR1, FLT3, GFER, GRK5, GSK3B, HCK, HSD17B1, IKBKE, JAK2, JAK3, LMNA, LRRK2, MAPK10, MARK3, MARK4, NFKB1, NQO2, PIK3CA, PIK3CB, PIM1, PRKCQ, PTK2, RET, ROCK2, SGK2, STK3, TAOK1, TBK1, TYR |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 5.062E-05 | 3.361E-03 | ACHE, ACVR1, HSD17B1, IGF1R, NQO2 |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 5.418E-05 | 3.565E-03 | BCL2, PIK3CA, PTK2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.565E-05 | 4.192E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 6.557E-05 | 4.192E-03 | AURKB, CDK1, JAK2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.565E-05 | 4.192E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 8.396E-05 | 5.224E-03 | AXL, BCL2, BTK, FLT3, GSK3B, IKBKE, JAK2, JAK3, NFKB1, PTGS2 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 8.703E-05 | 5.384E-03 | ACHE, ACVR1, BCL2, CAMK2A, FGFR1, FLT3, LRRK2, MAP3K10, NFKB1, NQO2, PDGFRA, PTGS2, TYR |
| MF | Unclassified; | GO:0004872; receptor activity | 9.649E-05 | 5.836E-03 | ACVR1, AHR, ALK, AXL, ESR1, ESR2, FGFR1, FLT1, FLT3, IGF1R, KDR, LTK, MET, NPSR1, PDGFRA, RET, ROS1, TSHR, TYRO3 |
| BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 1.048E-04 | 6.245E-03 | BCL2, PIK3CA, PTGS2, RET, TBK1 |
| BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 1.048E-04 | 6.245E-03 | FGFR1, MET, PDGFRA, PIK3CA, PIK3CB |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.097E-04 | 6.505E-03 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.103E-04 | 6.506E-03 | AURKB, BCL2, CDK1, CYP1A1, NOX4, POLB, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0010508; positive regulation of autophagy | 1.207E-04 | 7.029E-03 | CAMKK2, KDR, LRRK2, PIK3CB, TBK1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.265E-04 | 7.288E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.308E-04 | 7.382E-03 | CDK1, FGFR1, IGF1R, PDGFRA |
| BP | GO:0032501; multicellular organismal process | GO:0014042; positive regulation of neuron maturation | 1.309E-04 | 7.382E-03 | BCL2, RET |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.309E-04 | 7.382E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.309E-04 | 7.382E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.309E-04 | 7.382E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.460E-04 | 7.987E-03 | JAK2, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.673E-04 | 8.929E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.721E-04 | 9.125E-03 | CYP1A1, CYP1A2, CYP3A4, KDM4E |
| BP | GO:0002376; immune system process | GO:0045088; regulation of innate immune response | 1.769E-04 | 9.349E-03 | BTK, ESR1, HCK, IKBKE, JAK2, MMP2, NFKB1, TBK1, TYRO3 |
| BP | GO:0009987; cellular process | GO:2001235; positive regulation of apoptotic signaling pathway | 1.846E-04 | 9.661E-03 | BCL2, GSK3B, JAK2, MMP9, RET, STK3 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.901E-15 | 6.787E-13 | ACVR1, BCL2, CAMK1D, CAMK2A, CAMKK2, CDK1, CSNK2A1, DYRK1A, GSK3B, LRRK2, MAP3K10, TBK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.962E-13 | 3.335E-11 | RET, PDGFRA, GSK3B, ROCK2, FLT3, MMP1, MMP2, PIK3CB, PTGS2, MMP9, NFKB1, PTK2, IGF1R, MAPK10, PIK3CA, BCL2, MET, FGFR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.743E-11 | 3.181E-09 | PDGFRA, GSK3B, FLT1, PIK3CB, PTK2, NFKB1, IGF1R, PIK3CA, KDR, BCL2, JAK2, SGK2, JAK3, MET, FGFR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.350E-10 | 4.589E-09 | PIK3CA, ROCK2, MMP2, CAMK2A, KDR, PIK3CB, ESR1, MMP9, MET, PTK2, FGFR1, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.275E-10 | 4.589E-09 | MAPK10, PDGFRA, GSK3B, FLT1, PIK3CA, ROCK2, KDR, BCL2, PIK3CB, MET, PTK2, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 6.092E-10 | 1.726E-08 | GSK3B, TBK1, PIK3CA, CSNK2A1, PRKCQ, PIK3CB, JAK2, JAK3, IKBKE, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.266E-09 | 3.075E-08 | MAPK10, GSK3B, PIK3CA, PIK3CB, JAK2, ESR1, NFKB1, ESR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 6.743E-09 | 1.193E-07 | MAPK10, PDGFRA, TBK1, FLT1, PIK3CA, KDR, PIK3CB, MET, NFKB1, FGFR1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.720E-09 | 5.780E-08 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, PTGS2, CYP19A1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 7.017E-09 | 1.193E-07 | PDGFRA, GSK3B, PIK3CA, BCL2, PIK3CB, NFKB1, FGFR1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.921E-08 | 2.512E-07 | MAPK10, PIK3CA, MMP2, PIM1, BCL2, PIK3CB, JAK2, NFKB1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.922E-11 | 4.589E-09 | CA12, CA2, CA4, CA7, CA9, CA14 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 1.339E-08 | 1.897E-07 | GSK3B, HCK, PIK3CA, GRK5, ROCK2, PIK3CB, JAK2, JAK3, NFKB1, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 2.791E-08 | 3.163E-07 | MAPK10, GSK3B, TBK1, CSNK2A1, PIK3CA, BCL2, CDK1, PIK3CB, JAK3, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.950E-09 | 1.229E-07 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.225E-08 | 2.701E-07 | RET, PDGFRA, PIK3CA, FLT3, PIK3CB, MET, FGFR1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.390E-07 | 3.390E-06 | MAPK10, TBK1, PIK3CA, BCL2, PIK3CB, MMP9, IKBKE, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 2.740E-07 | 2.911E-06 | ACVR1, GSK3B, PIK3CA, PIK3CB, JAK2, JAK3, FGFR1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 4.440E-07 | 4.193E-06 | FLT1, PIK3CA, CAMK2A, BCL2, PIK3CB, NFKB1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 1.341E-06 | 1.086E-05 | MAPK10, GSK3B, TBK1, PIK3CA, PIK3CB, JAK2, IKBKE, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.480E-07 | 7.587E-06 | PDGFRA, PIK3CA, PIK3CB, MET, FGFR1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.252E-06 | 1.064E-05 | MAPK10, GSK3B, PIK3CA, CAMK2A, BCL2, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.496E-06 | 1.929E-05 | MAPK10, GSK3B, TBK1, PIK3CA, PIK3CB, IKBKE, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 5.393E-06 | 3.526E-05 | PDGFRA, FLT1, PIK3CA, KDR, PIK3CB, MET, FGFR1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.821E-06 | 1.998E-05 | MAPK10, GSK3B, PIK3CA, CAMK2A, PIK3CB, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 2.636E-06 | 1.948E-05 | PIK3CA, BCL2, PIK3CB, PTGS2, NFKB1, PTK2 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 5.649E-06 | 3.554E-05 | MAPK10, PIK3CA, CAMK2A, PRKCQ, ALOX12, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 7.803E-06 | 4.279E-05 | CAMK1D, PIK3CA, ROCK2, CAMK2A, PIK3CB, PTGS2, CAMKK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 5.991E-06 | 3.554E-05 | PIK3CA, MMP2, PIK3CB, ESR1, MMP9, ESR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 7.803E-06 | 4.279E-05 | PIK3CA, THPO, PIM1, BCL2, PIK3CB, JAK2, JAK3 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 8.402E-06 | 4.375E-05 | PDGFRA, PIK3CA, PIM1, BCL2, CYP1B1, PTGS2, MMP9, MET, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 4.166E-06 | 2.833E-05 | CSNK2A1, BCL2, BTK, PRKCQ, PTGS2, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 8.892E-06 | 4.446E-05 | MAPK10, TBK1, PIK3CA, PIK3CB, IKBKE, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.159E-05 | 5.066E-05 | ACHE, PIK3CA, CAMK2A, BCL2, PIK3CB, JAK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.100E-05 | 5.056E-05 | MAPK10, PIK3CA, PIK3CB, PTGS2, MMP9, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.044E-05 | 4.930E-05 | MAPK10, GSK3B, PIK3CA, PRKCQ, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 6.063E-06 | 3.554E-05 | PIK3CA, FLT3, PIM1, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.644E-05 | 6.771E-05 | MAPK10, PIK3CA, BCL2, PIK3CB, JAK2, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 8.492E-06 | 4.375E-05 | PIK3CA, KDR, PIK3CB, PTGS2, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.823E-05 | 7.042E-05 | FLT1, FLT3, MMP9, MET, NFKB1, PTK2, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 3.471E-05 | 1.255E-04 | MAPK10, PIK3CA, ROCK2, CAMK2A, PIK3CB, NFKB1, TSHR |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 1.644E-05 | 6.771E-05 | PIK3CA, ROCK2, MMP2, PIK3CB, MMP9, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 9.204E-06 | 4.471E-05 | MAPK10, GSK3B, PIK3CA, BCL2, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.809E-05 | 7.042E-05 | MAPK10, PIK3CA, ROCK2, BCL2, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 2.175E-05 | 8.038E-05 | MAPK10, TBK1, CSNK2A1, CDK1, JAK2, IKBKE, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.162E-05 | 5.066E-05 | PDGFRA, PIK3CA, CAMK2A, PIK3CB, IGF1R |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 4.322E-05 | 1.499E-04 | MAPK10, PIK3CA, LMNA, BCL2, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 4.679E-05 | 1.591E-04 | MAPK10, GSK3B, CSNK2A1, ROCK2, CSNK1A1, CAMK2A |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.054E-05 | 7.760E-05 | GSK3B, PIK3CA, BTK, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 1.642E-04 | 5.075E-04 | MAPK10, PDGFRA, TAOK1, NFKB1, MAP4K4, FGFR1, STK3 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.807E-04 | 5.388E-04 | RET, PDGFRA, FLT1, GRK5, KDR, MET, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 1.764E-04 | 5.355E-04 | POLB, PDGFRA, GSK3B, PIK3CA, PIK3CB, JAK3, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 1.673E-05 | 6.771E-05 | MAPK10, PRKCQ, JAK2, NFKB1, CAMKK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 8.493E-05 | 2.777E-04 | MAPK10, PIK3CA, CDK1, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 6.964E-05 | 2.321E-04 | PIK3CA, PIK3CB, NFKB1, CAMKK2, IGF1R |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 2.078E-04 | 6.092E-04 | ACVR1, PDGFRA, FLT1, THPO, FLT3, KDR, MET |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.126E-04 | 3.611E-04 | GSK3B, PIK3CA, PRKCQ, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 3.484E-04 | 9.255E-04 | POLB, PIK3CA, CDK1, PIK3CB, JAK3, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.613E-05 | 1.280E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.427E-04 | 9.255E-04 | MAPK10, PIK3CA, BTK, PIK3CB, NFKB1 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 4.378E-04 | 1.106E-03 | PDGFRA, PIK3CA, ROCK2, PIK3CB, PTK2, FGFR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.548E-04 | 9.280E-04 | MAPK10, PIK3CA, PIK3CB, SGK2, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 6.336E-04 | 1.561E-03 | MAPK10, GSK3B, PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 1.324E-03 | 3.000E-03 | MAPK10, CAMK2A, BCL2, JAK2, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 2.615E-04 | 7.408E-04 | MAPK10, PIK3CA, BTK, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 1.170E-03 | 2.724E-03 | MAPK10, PDGFRA, PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 1.127E-03 | 2.661E-03 | PIK3CA, PIK3CB, NFKB1, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.304E-03 | 2.995E-03 | MAPK10, PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 2.340E-03 | 4.973E-03 | PIK3CA, ROCK2, BTK, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.330E-04 | 6.714E-04 | MAPK10, PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.229E-04 | 3.870E-04 | PIK3CA, PIK3CB, PTGS2, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.073E-03 | 4.518E-03 | GSK3B, PIK3CA, PIK3CB, ESR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 2.483E-03 | 5.210E-03 | PIK3CA, PIK3CB, IGF1R, CAMKK2 |
| 09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 2.707E-03 | 5.612E-03 | GSK3B, ROCK2, MET, PTK2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.434E-04 | 9.255E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 3.743E-03 | 7.149E-03 | MAPK10, GSK3B, PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.677E-03 | 8.641E-03 | PIK3CA, CAMK2A, BCL2, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 4.424E-04 | 1.106E-03 | PIK3CA, PIK3CB, MET, PTK2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04622 | RIG-I-like receptor signaling pathway | 2.923E-04 | 8.147E-04 | MAPK10, TBK1, IKBKE, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.618E-04 | 9.320E-04 | CSNK2A1, MET, FGFR1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 4.504E-03 | 8.413E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 4.504E-03 | 8.413E-03 | PTGS2, JAK2, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.107E-03 | 6.288E-03 | PIK3CA, PIK3CB, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 3.390E-03 | 6.624E-03 | PIK3CA, PIK3CB, MET |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.689E-03 | 7.126E-03 | MAPK10, MET, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.247E-03 | 6.418E-03 | CYP1A2, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 3.247E-03 | 6.418E-03 | MAPK10, ROCK2, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04623 | Cytosolic DNA-sensing pathway | 3.107E-03 | 6.288E-03 | TBK1, IKBKE, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.122E-03 | 4.566E-03 | ALK, PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.714E-03 | 3.784E-03 | GSK3B, PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.359E-03 | 3.040E-03 | MAPK10, PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 8.571E-04 | 2.052E-03 | MMP1, MMP2, MMP9 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.970E-04 | 1.936E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 4.868E-03 | 8.899E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Exudative age-related macular degeneration | H35.3 | FLT1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; JAK2; BCL2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; BCL2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; IKBKE; MMP1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; MMP2; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | FLT1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | FGFR1; CA9; BCL2; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; RET; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; JAK2; |
| C00-D49: Neoplasms | Myeloproliferative disorder | C94.6 | JAK2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; PIK3CA; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; PTK2; IGF1R; PIK3CA; KDR; FGFR1; FLT3; MMP9; PDGFRA; MELK; RET; ROS1; PIK3CB; MMP2; CA9; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | FLT1; |
| I00-I99: Diseases of the circulatory system | Peripheral arterial occlusive disease | I73.9 | FGFR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Polycythemia vera | D45 | JAK2; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; JAK2; BCL2; |
| I00-I99: Diseases of the circulatory system | Severe coronary heart disease | I25.1 | FGFR1; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; PTK2; IGF1R; PIK3CA; KDR; FGFR1; CSNK2A1; NFKB1; FLT3; ACHE; MMP9; FLT1; PTGS2; TNK2; JAK2; RET; PIK3CB; NQO2; MMP2; GSK3B; CA9; BCL2; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | JAK2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; FLT1; CA9; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | FLT1; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; JAK2; NQO2; CYP19A1; CA9; BCL2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; BCL2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; FLT1; PTGS2; MMP2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; CAMK2A; ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| C00-D49: Neoplasms | Bladder cancer | C67 | FLT1; CYP19A1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | FLT1; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | PDGFRA; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; PTGS2; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; FLT1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; PDGFRA; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | ALK-positive advanced or metastatic NSCLC | C33, C34 | ROS1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | PDGFRA; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; PRKCQ; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Neovascular age-related macular degeneration | H35.3 | FLT1; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Hereditary hemorrhagic telangiectasia | I78.0 | FLT1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | FGFR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| P00-P96: Certain conditions originating in the perinatal period | Central nervous system injury | P11.9 | MAPK10; |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | FGFR1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PDGFRA; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; PTGS2; GSK3B; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; RET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2; MARK3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; PDGFRA; MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| NA: NA | Myeloproliferative neoplasm | NA | JAK2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; JAK2; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2A; PTGS2; ROCK2; MMP1; TYR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Anemia | D50-D64 | JAK2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
